Stevanato's GLP-1 Tailwind Just Became One Customer's Inventory Problem
A clean Q3 and a reiterated guide masked the only thing that mattered: 2027 growth cut to low single digits because one originator pulled Nexa syringe volumes
STVN · Earnings Call · 2026-11-03
The Quarter Was Fine. The Forward Curve Was Not.
Stevanato Group reported a genuinely unremarkable third quarter on 2026-11-03: revenue of EUR 326.1 million, up 8% both reported and organic; high-value solutions at EUR 149.4 million (+1%) and 46% of the top line; adjusted EBITDA of EUR 88.8 million for a 27.2% margin, up 150 basis points; net profit +16% to EUR 41.8 million. Full-year guidance was reiterated in full — EUR 1.26–1.28 billion of revenue, EUR 335–345.2 million of adjusted EBITDA, EUR 0.60–0.62 of adjusted diluted EPS. There was even a small trophy: Fishers broke even at the gross profit line. And yet the entire call was about 2027. That is because the thing that has been Stevanato's most reliable growth engine for six straight quarters — the GLP-1 class — has stopped behaving like one, at least at one account. “Within our GLP portfolio, we now expect lower volumes than previously anticipated for 2027.” — Franco Stevanato, Chairman and Chief Executive Officer · 2026-11-03 GLP-1 revenue fell to roughly 17–18% of total company revenue in Q3, from 21–22% in Q1 and 22–23% in Q2. That is a deceleration management had not telegraphed a quarter ago.One Customer, One Format
Analysts pushed hard on the shape of the problem, and Franco Stevanato was unusually specific on scope even while staying silent on identity: “I confirm that this temporary headwind in 2027, it is tied to one customer.” — Franco Stevanato, Chairman and Chief Executive Officer · 2026-11-03 Later, under questioning from Justin Bowers, he narrowed it further: “this temporary headwind that we are facing 2027 is related to Nexa syringes, and we don't have up to now other headwind in 2026 or 2027.” — Franco Stevanato, Chairman and Chief Executive Officer · 2026-11-03 Not cartridges, not vials, not the device pipeline. Engineering's order delays trace to the same counterparty. So the temporary headwind is a concentration event, not a market event. The framing matters: a single customer deferring volume is a timing problem you can backfill; a drug class losing penetration is a thesis problem you cannot. Management is betting the market accepts the first reading. Larry Solow's challenge — that the customer may simply have lost share to the other horse in a two-horse race — went unanswered beyond a flat denial of share loss.The Credibility Ledger
Here is where prior calls earn their keep. In August, the same CFO described GLP volumes with a word you cannot use twice in a row without consequence: “They are predictable volumes for us in 2026 because we are largely covered by contractual commitments from our customers.” — Marco Dal Lago, Chief Financial Officer · 2026-05-07 In March, guidance assumed GLP growth “in the range of mid-teens” — Franco Stevanato, Chairman and Chief Executive Officer · 2026-03-04 for 2026. Nine months later GLP revenue is declining year-over-year in a quarter, and the company is booking variable compensation because a customer took less than its committed binding forecast. That compensation is the second thread. It surfaced in Q2 and management declined to size it then: “No, it's not impacting in a significant way the quarter.” — Marco Dal Lago, Chief Financial Officer · 2026-08-04 On this call, David Windley asked twice and Marco Dal Lago deflected twice — “it's not relevant in the quarter in the year” — Marco Dal Lago, Chief Financial Officer · 2026-11-03 — before conceding the clause set (take-or-pay, minimum quantities, capacity reservation, capex contribution, share protection) cannot be disclosed. Worth noting the accounting choice: the compensation was booked in other containment and delivery solutions rather than high-value solutions or GLP revenue, explicitly so as not to inflate either KPI. That is honest — and it also means the headline high-value mix flattered the underlying relationship.What Management Stopped Saying
For five calls running, GLP-1 was the elegant answer: a phenomenal drug class, patient penetration below 10%, the tip of the iceberg, double-digit growth for years. That language is now doing different work. On Tuesday GLP-1 was the reason the long-range plan slipped rather than the reason it existed.What replaced it is the biosimilar and broader biologics story: non-GLP biologics grew over 30% in the quarter and 13% year to date, more than 30 customers and 50 programs in flight, Alba syringe capacity being added in Italy, and ready-to-fill cartridges described as booked for most of 2027. Underneath sits a real structural push — European Annex 1 sterility rules nudging pharma from bulk to ready-to-fill formats, a question analysts have asked in consecutive quarters and management has answered qualitatively both times, never with a number. The quieter tell is engineering. For a year that segment was an operations story — site acceptance tests doubling, centers of excellence, a pipeline about to convert. On Tuesday it became a strategic one. Franco, unprompted, on visual inspection and assembly: “We continue to assess internally what is the best interest from strategic point of view in order to serve better our customers.” — Operator, Conference Operator · 2026-11-03 That is divestiture language. Stevanato already sold the California Balda C. Brewer operation in 2026 on precisely the logic that non-strategic industrial assets dilute the biologics narrative, and Franco repeated it here, calling inspection and assembly dilutive to our corporate margin. Engineering revenue is now guided to EUR 124–134 million for the year at a 1.1% operating margin. Nobody should be shocked if that segment is next on the block.Without this temporary headwind in 2027, we believe that we would have grown in line with our long-range plan of high single digits to low double digits in 2027.